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A major goal for immunotherapy is to tolerize the immune cells
that coordinate tissue damage in autoimmune and alloantigen
responses. CD4 T cells play a central role in many of these conditions
and improved antigen-specific regulation or removal of these cells
could revolutionize current treatments. A confounding factor is that
little is known about whether and how tolerance is induced in
memory CD4 T cells. We used MHC class II tetramers to track and
analyze a population of endogenous antigen-specific memory CD4 T
cells exposed to soluble peptide in the absence of adjuvant. We
found that such memory T cells proliferated and reentered the
memory pool apparently unperturbed by the incomplete activation
signals provided by the peptide. Upon further restimulation in vivo,
CD4 memory T cells that had been previously exposed to peptide
proliferated, provided help to primary responding B cells, and
migrated to inflamed sites. However, these reactivated memory cells
failed to survive. The reduction in T-cell number was marked by low
expression of the antiapoptotic molecule B cell lymphoma 2 (Bcl2)
and increased expression of activated caspase molecules. Conse-
quently, these cells failed to sustain a delayed-type hypersensitivity
response. Moreover, following two separate exposures to soluble
antigen, no T-cell recall response and no helper activity for B cells
could be detected. These results suggest that the induction of
tolerance in memory CD4 T cells is possible but that deletion and
permanent removal of the antigen-specific T cells requires reactiva-
tion following exposure to the tolerogenic antigen.
Immune memory is an important characteristic of the adaptiveimmune response with memory cells responding quickly and
effectively upon reexposure to a pathogen (1–3). A number of
differences between naive and memory cells contribute to this
enhanced response. These include an increased sensitivity to the
antigen, an enhanced effector response, and an altered location
such that memory cells are positioned to act most effectively
before reinfection (4, 5).
Memory cells can, however, also respond to nonpathogenic
antigens such as autoantigens and alloantigens. In these instan-
ces, the superior responses of memory cells harm, rather than
benefit, the host. A major goal in the treatment of autoimmune
disease and in the prevention of transplant rejection is to remove
or tolerize immune cells that specifically recognize auto- or allor-
eactive antigens, respectively (6, 7).
CD4 T cells are central coordinators of specific immune
responses and as such play destructive roles in autoimmune
diseases and in the rejection of allografts (8, 9). Whereas the
signals involved in, and the molecular basis of, tolerance in-
duction in naive T cells has been extensively characterized (10,
11), much less is known about how, or even whether, functional
tolerance can be achieved in memory CD4 T cells. In comparison
with naive T cells, memory T cells are much less dependent on
costimulatory signals and are resistant to the induction of tol-
erance by molecules that block costimulatory pathways (12–14).
However, memory T cells do not always act independently of
costimulatory signals, suggesting that they may function abnormally
if reactivated by antigen delivered in the absence of these signals
(15, 16).
Soluble antigens are known to be good tolerogens for naive
T cells (17). Moreover activation of effector or memory CD4
T cells with soluble antigen can induce reduced cytokine pro-
duction, ex vivo proliferation, and the ability to cause inflammatory
disease (18–20). However, there is no clear understanding of the
fate of memory CD4 T cells activated with tolerizing signals
and little evidence to explain why their effector responses may
be reduced.
We therefore tested the effect of soluble antigen on memory
T cells in vivo using fluorescent MHC class II tetramer reagents
to track endogenous antigen-specific CD4 T cells and in vivo
readouts of T-cell function. We found that CD4 memory T cells
responded similarly to antigen delivered with or without adju-
vant. However, the ability of memory CD4 T cells to survive
further in vivo activation was severely limited following exposure
to tolerizing antigen. Our data demonstrate that tolerance in-
duction in memory CD4 T cells requires exposure to antigen at
least twice, information that is highly relevant for clinical studies
that aim to induce tolerance in memory CD4 T cells.
Results
Memory CD4 T Cells Proliferate and Up-Regulate Activation Markers
in Response to Soluble Antigen and Then Reenter the Memory Pool.
To determine the consequences of activating memory CD4 T
cells with antigen in vivo in the absence of overt costimulation,
we first needed to generate a population of antigen-specific
memory CD4 T cells that could be tracked. Memory cells were
generated by immunizing C57BL/6 (B6) mice with the protein
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IAb restricted peptide, 3K, delivered with lipopolysaccharide
(LPS). Mice immunized in this way are hereinafter referred to as
memory mice. We chose this form of immunization as it allowed
us to track an antigen-specific response using fluorescently la-
beled IAb/3K tetramers (Fig. 1). Our previous studies showed
that such memory cells respond in a typical anamnestic fashion:
in comparison with primary responding T cells, they reach their
peak proliferative response faster, make more effector cytokines,
and provide help to B cells more rapidly (21, 22).
To examine the response of memory CD4 T cells to antigen
delivered in the absence of exogenous adjuvant, we injected 3K
peptide i.v. alone into either control naive animals or memory
mice. Injection of 3K into naive mice did not increase the
numbers of IAb/3K-specific CD4 T cells measured 46 d later
(Fig. 1). Thus, the soluble peptide could not induce a sustained
immune response. Following immunization with 3K conjugated
to ovalbumin protein (3K-OVA) and delivered with the adjuvant
alum, the specific T cells in naive mice, or in mice previously
immunized with 3K + LPS expanded but no 3K-specific CD4
T cells could be detected in mice previously given 3K peptide
alone (Fig. 1 and Fig. S1). These data indicate that any 3K-
specific T cells present in animals injected with peptide alone
were either unable to respond to antigen or had been deleted.
Therefore, the soluble peptide was tolerogenic.
In contrast to the response of naive CD4 T cells, we found that
memory CD4 T cells increased in number following the injec-
tion of soluble peptide (Fig. 2A and Fig. S2A). Moreover, these
reactivated memory cells reentered the memory pool and de-
clined at a rate similar to that of memory CD4 T cells reactivated
with 3K and LPS. However, reduced numbers of IAb/3K tetra-
mer+ cells were found in memory mice injected with 3K peptide
alone compared with those reactivated with antigen and adjuvant.
We examined the ability of the reactivated memory cells to
enter the cell cycle to determine whether this reduction in cell
number was due to decreased proliferation. The percentages of
IAb/3K tetramer+ cells that were BrdU+ were examined before
and 3 or 5 d following reimmunization with 3K peptide injected
with or without LPS. Memory cells reactivated with peptide
alone were less likely than those reactivated with peptide and
LPS to be BrdU+ 3 and 5 d after the recall (Fig. 2B and Fig.
S2B). This demonstrates that, as expected, LPS acts as an ad-
juvant to drive T-cell proliferation (23). Despite their reduced
proliferative response, memory cells reactivated with peptide
alone up-regulated markers of activation, including programmed
cell death 1 (PD1) and inducible T-cell costimulator (ICOS)
(Fig. 2 C and D). ICOS expression was slightly less well sustained
on IAb/3K tetramer+ cells from mice injected with peptide alone.
To determine whether memory cell reactivation with or
without adjuvant led to an alteration in the phenotype of the
resultant memory cells, we examined the expression of a variety
of cell-surface or intracellular molecules. We examined mole-
cules important in cell survival [CD127, B cell lymphoma 2
(Bcl2)], costimulatory and inhibitory molecules (CD28, CD27,
ICOS, and PD1) and chemokine receptors (CCR7 and
CXCR5). Regardless of the presence of LPS during memory
cell reactivation, the expression of these molecules was the same
on the memory IAb/3K tetramer+ cells (Fig. 2E and Fig. S2C).
These data suggest that despite the slightly reduced T-cell response
in memory mice reactivated with peptide alone, cells of a similar
phenotype repopulate the memory pool.
Memory Cells Exposed to Soluble Peptide Fail to Induce a Sustained
Delayed-Type Hypersensitivity Response. To find out whether or
not the memory CD4 T cells that had been previously exposed to
soluble antigen in the absence of adjuvant were functional, we
tested their ability to drive a delayed type hypersensitivity (DTH)
response, a characteristic of T helper 1 memory CD4 T cells (24).
The 3K peptide conjugated to OVA protein was injected into the
footpads of previously immunized animals. Mice that had been
immunized once or twice with 3K peptide and LPS showed in-
creased and prolonged footpad swelling (Fig. 3A). However,
mice primed with 3K and LPS then injected with 3K peptide
alone, had a significant increase in footpad swelling only on day 2
after the footpad injection. These data suggested that, whereas
CD4 memory T cells exposed to soluble peptide may traffic to
the DTH draining lymph node, they might fail to respond com-
pletely after they have reached the site.
To distinguish between these possibilities, we measured the
numbers of IAb/3K-specific CD4 T cells in the draining popliteal
lymph node. The numbers and percentages of IAb/3K tetramer+
cells were found to be above background in the draining lymph
nodes of mice that had been immunized once or twice with 3K
and LPS and also in memory mice that had been injected with 3K
alone 2 d after footpad injection (Fig. 3B and Fig. S3A). There
were more memory cells in the draining lymph nodes of mice
immunized twice with 3K and LPS than in memory mice that had
been injected with 3K alone; however, this probably reflected the
difference in the total number of antigen-specific cells in these
animals (Fig. S3B).
By day 8, the numbers of IAb/3K tetramer+ cells in the
draining lymph node had increased in mice previously immu-
nized once or twice with 3K and LPS. However, the numbers of
specific cells remained the same in memory mice injected with
3K (Fig. 3B and Fig. S3A). This result, in combination with the
failure of these cells to induce a sustained DTH response, sug-
gested that once recruited to the DTH site, the memory cells
were either unable to respond or to survive.
To distinguish between these two possibilities, we examined
the surface expression of the high-affinity interleukin-2 receptor,
CD25, on the activated T cells. Between 15% and 20% of IAb/
3K tetramer+ cells in the draining lymph nodes of memory mice
were CD25+ 2 d following footpad injection, regardless of their
previous immunization history (Fig. 3C). In contrast, splenic IAb/
3K tetramer+ cells from these animals, which had not been ex-
posed to the antigen, did not up-regulate CD25. These data in-
dicate that memory cells exposed to antigen in the absence of
adjuvant are activated following migration to inflamed sites.
Fig. 1. Immunization with 3K peptide and LPS generates memory CD4
T cells but injection of 3K into naive animals leads to antigen-specific T-cell
tolerance. Naive B6 mice were injected with 3K peptide or 3K peptide and
LPS i.v. and the percentages of live CD4+ dump negative cells that were
IAb/3K tetramer+ CD44hi in the spleen examined 46 d later (Upper row).
Alternatively, 40 d following immunization, these mice and naive controls
were immunized with 3K-OVA delivered with alum i.p. and the percen-
tages of IAb/3K tetramer+ CD44hi out of live CD4+ dump negative cells
examined in the spleen after a further 6 d (Lower row). The data are
representative plots from two experiments with four mice per group. The
cells are gated on CD4+ live lymphocytes that do not express CD8, F4/80,
MHC II, and B220. The numbers indicate the percentages of gated CD4 T
cells that are CD44hi IAb/3K tetramer+.
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Memory Cells Exposed to Soluble Peptide Fail to Survive Following
Reactivation in Vivo. The apparent failure of memory cells ex-
posed to soluble peptide to survive reactivation in the footpad
may have been confounded by the lack of adjuvant in the final
immunization. In addition, this local immunization did not
reactivate all of the animal’s memory cells. To address these
points, we systemically immunized memory mice that had or had
not been exposed to tolerance signals with 3K-OVA delivered
with the adjuvant alum. In some of these experiments, we in-
cluded LPS in the final immunization; however, this did not alter
the subsequent T-cell responses.
Memory cells generated by either one or two immunizations
with 3K peptide and LPS increased in number following reac-
tivation with 3K-OVA and alum and then entered a normal
contraction phase. However, whereas memory CD4 T cells that
had been reactivated with soluble peptide alone initially increased
in number, the cells entered a rapid decline such that by day 9,
their numbers were barely above the limit of detection (Fig. 4A).
The change in cell survival after day 6 was not due to a dif-
ference in cell proliferation as all memory cells incorporated
similar levels of BrdU at this time point (Fig. 4B). In addition,
the memory cells expressed similar levels of the activation mol-
ecules PD1 and ICOS at day 6 (Fig. 4 C and D). In contrast,
memory cells exposed to antigen in the absence of adjuvant were
more likely to contain active caspase 3 and 7 and expressed lower
levels of the prosurvival molecule, Bcl2 (Fig. 4 E and F and Fig. S4).
Therefore, whereas memory CD4 T cells exposed to antigen in the
absence of adjuvant can certainly respond to reactivation, they fail
to survive this process.
Fig. 2. Memory cells are activated and reenter the memory pool following exposure to antigen in the absence of adjuvant. B6 mice immunized (Imm) with
3K peptide and LPS i.v 40 d previously (Imm1) were injected with 3K + LPS or 3K without adjuvant (Imm2). The numbers of IAb/3K tetramer+ CD44hi cells in the
spleens of these mice were examined 3, 5, and 40 d after Imm2 (A). Some of these animals were injected with BrdU 15 h before the percentages of CD44hi
IAb/3K tetramer+ BrdU+ were examined on days 3 and 5 after Imm2 (B). The expression of PD1 (C ) or ICOS (D) on the CD44hi IAb/3K tetramer+ was ex-
amined before and 3 or 5 d after Imm2. The phenotype of the IAb/3K tetramer+ memory cells was examined at 40 d after Imm2 (E ). In A–D, each point
shows the mean of the group and error bars are SEM. The data are combined from two individual experiments with a total of six to eight mice per group
per time point. In A, the x axis is set at the limit of detection as determined by staining spleen cells from naive animals. In E, the cells are gated on IAb/3K
tetramer+ cells reactivated with 3K and LPS (red line) or 3K alone (blue dashed line) or total naive CD4 cells (filled histogram). The data are representative
FACS plots from two experiments with three to four mice per group.
Fig. 3. Memory CD4 T cells exposed to tolerance signals fail to sustain a DTH response. B6 mice immunized with 3K peptide with/without LPS i.v. as indicated
were injected with 3K-OVA in the footpad 40 d after Imm2. The mice’s footpads were measured each day and the percentage change in footpad thickness
was calculated (A). The numbers of IAb/3K tetramer+ cells in the popliteal lymph node draining the injected footpad were examined 0, 2, or 8 d after footpad
injection (B). The percentages of IAb/3K tetramer+ cells in the spleen or draining lymph node that were CD25+ were examined 2 d following the footpad
injection (C). Data are combined from two to three independent experiments with three to four mice per group. In A, the symbols above the graph show
significant differences in footpad swelling of the different groups compared with that in naive animals injected with 3K-OVA on the indicated days. Mice
immunized once with 3K + LPS: P < 0.05 = ζ; P < 0.01 = ζζ; P < 0.001 = ζζζ. Mice immunized once with 3K + LPS and once with 3K: P < 0.01 = ωω. Mice
immunized twice with 3K + LPS: *P < 0.05; **P < 0.01; ***P < 0.001. In A and B, each symbol on the graph represents the mean of the group and error bars are
SEM. In B, level of background staining is indicated by the day 0 time point of the primary immunized mice. In C, each symbol represents a mouse and the
horizontal line shows the mean of the group.
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Memory CD4 T Cells Exposed to Soluble Antigen Provide Accelerated
Help to B Cells.We recently demonstrated that CD4 memory T cells
provide accelerated help to primary responding B cells to produce
an early class-switched antibody response (22). This ability
was contained within a population of memory T cells that
expressed CXCR5 at a high level. CXCR5 expression was similar
on memory cells that had been reactivated in the absence or
presence of adjuvant (Fig. 2E), suggesting that both populations
may be able to provide this accelerated help. However, the poor
survival of memory cells previously activated with antigen alone
might suggest that they would be unable to interact successfully
with naive B cells.
We tested whether this was the case by measuring the amount
of anti-OVA IgG in the serum of memory mice reimmunized
with 3K-OVA delivered with alum. At the early time point, day 5,
primary responding animals made at most a small anti–OVA-
specific response (Fig. 5). Mice that had been previously exposed
once or twice to 3K and LPS produced plenty of anti-OVA, with
mice primed twice producing more than those that had been primed
only once, probably because they contained more 3K-specific T cells
(day 0 in Fig. 4A). Therefore, the OVA-specific antibody at this
time point is dependent on help provided by 3K-specific memory
cells rather than help from either primary responding 3K- or OVA-
specific CD4 T cells.
Memory mice that had been immunized once with 3K and LPS
contained similar numbers of IAb/3K-specific cells to memory
mice reactivated with 3K peptide (Fig. 4A). The animals in these
two groups made a similar anti-OVA IgG response. Therefore,
despite their poor survival following reactivation, memory CD4
T cells that had been reactivated with antigen alone can still
provide accelerated help to B cells.
Memory CD4 T Cells Are Deleted Following Exposure to Two Injections
of Soluble Peptide. As memory CD4 T cells exposed to soluble
antigen undergo apoptosis following further reactivation with
antigen delivered with (Fig. 4) or without (Fig. 3) adjuvant, we
reasoned that two injections of soluble antigen should lead to
a loss of the antigen-specific T cells and the accelerated antibody
responses. To test this, mice containing IAb/3K-specific cells were
injected twice with 3K peptide i.v. 40 d apart. After an additional
40 d, these and control mice were immunized with 3K-OVA and
alum. As expected (22), antigen-specific T cells could not be
readily detected in primary immunized animals or in animals that
had been injected twice with soluble peptide at this early time
point. No IAb/3K tetramer+ cells above background could be
detected in memory mice injected twice with 3K peptide 6 d after
immunization (Fig. 6A and Fig. S5). Moreover, the anti-OVA
response in these animals was the same as that in naive mice
immunized with 3K-OVA and alum (Fig. 6B). Together these data
demonstrate that deletional tolerance can be induced in memory
CD4 T cells provided they are reactivated following exposure to
the tolerizing antigen.
Discussion
Immunological memory is crucial as it protects the host from
invaders to which it has previously been exposed. The superior
responses of memory cells means that they are adept at re-
sponding to such pathogens, providing a larger and more rapid
immune response. Protective immune memory is often consid-
ered a function of high-affinity antibody and killer CD8 T cells
(1, 3). Memory CD4 T cells also play crucial roles in protecting
Fig. 4. Memory cells exposed to tolerance signals respond to further reac-
tivation but fail to accumulate. B6 mice immunized with 3K with/without LPS
i.v. as indicated were injected with 3K-OVA and alum i.p. 40 d after Imm2.
After an additional 4, 6, or 9 d, the numbers of splenic IAb/3K tetramer+ cells
were determined (A). Each point shows the mean of a total of 7–27 mice
from seven separate experiments; error bars are SEM. The x axis is set at the
limit of detection as determined by staining spleen cells from naive animals.
On days 3–6 after Imm3, these mice were given drinking water containing
BrdU and the percentages of CD44hi IAb/3K tetramer+ cells that were BrdU+
in each mouse were determined 6 d later (B). Each point represents one
mouse and the line shows the mean of the group. Alternatively, the levels of
expression of PD1 (C), ICOS (D), active caspase 3 and 7 (E), and Bcl2 (F) were
determined in the antigen-specific CD4 T cells. In all experiments, data are
representative of one to three independent experiments with three to four
mice per group per time point.
Fig. 5. Memory CD4 T cells reactivated with antigen alone can provide help
to B cells. B6 mice immunized with 3K with/without LPS i.v. as indicated were
injected with 3K-OVA and alum i.p. 40 d after Imm2. After an additional 6 d,
the amount of anti–OVA-specific IgG in the serum was examined. The data
are combined from two independent experiments with four mice per group.
Significant differences between the groups and primary responding mice are
indicated by *P < 0.05, ***P < 0.001; ns, not significant, error bars are SEM.
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the host from a diverse range of pathogens, including bacteria,
viruses, and parasites (25–27).
The ability of memory CD4 T cells to respond in the absence
of heightened costimulation presents a major hurdle for strate-
gies that aim to induce specific T-cell tolerance in previously
activated T cells (6, 7). In the experiments described here, we use
a well-established method of tolerizing antigen-specific cells, the
administration of antigen in the absence of components that
stimulates innate immunity, an adjuvant. This method has been
used for many years to tolerize, via deletion or the induction of
anergy, naive lymphocytes (17, 28). However, its ability to tol-
erize memory CD4 T cells has not previously been examined in
detail. Here we show that, unlike naive T cells, memory CD4 T
cells respond very similarly to antigen given with or without
adjuvant. The reactivated memory cells return to the memory
and respond to further reactivation by up-regulating costimulatory
molecules, migrating to inflamed lymph nodes, entering the cell
cycle, and providing help to B cells. Together, these data strengthen
the argument that memory CD4 T cells are intrinsically distinct
from naive CD4 T cells (4).
Memory CD4 T cells were, however, permanently altered
following activation with antigen alone. Despite normal expres-
sion of prosurvival molecules and long-term survival within the
memory pool, further in vivo reactivation led to apoptotic cell
death. The activation of either naive or memory T cells following
immunization with antigen and adjuvant leads to a burst of cell
proliferation followed by the death of the majority of the acti-
vated cells. Memory CD4 T cells previously exposed to antigen
briefly expanded but entered a dramatic contraction phase that
led to the deletion of the antigen-specific T cells. Taken to-
gether, these data indicate that these cells misinterpret activation
signals, turning what should be a signal to increase in number
into a signal to undergo cell death.
The molecular changes that underlie this altered survival remain
unclear. Whereas costimulatory signals that promote T-cell acti-
vation and cell survival are closely linked (29), the intracellular
molecules that transmit these signals can be distinct (30, 31). That
the defect in cell survival occurs following further activation sug-
gests that the stress induced by T-cell activation initiates apoptosis
in the memory cells. T-cell activation leads to increased expression
of proteins involved in autophagy allowing cells to maintain energy
and nutrients during proliferation (32, 33). Autophagy and apo-
ptosis are cellular pathways that can coregulate each other (34).
We speculate that restimulated memory cells previously exposed
to antigen alone fail to induce autophagy pathways that prevent
immediate cell death. Intriguingly, inhibition of mammalian target
of rapamycin, an inhibitor of autophagy, promotes the generation
of memory CD8 T cells (35).
Injection of soluble antigen or altered peptide ligands into ani-
mals with ongoing autoimmune or allergic responses can lead to
a reduction in disease (20, 36–40). The mechanisms or correlates of
protection in these models vary from the induction of IL-10 pro-
ducing cells (37, 39, 40), to reduced specific T-cell (20, 36) and
antibody responses (38). Our data support the idea that the path-
ogenic T cells themselves are altered following administration of
soluble antigen and that a double dose of soluble antigen is required
to induce full tolerance. These different mechanisms of tolerance
suggest that the initial generation of the memory cells may influence
whether and how tolerance can be subsequently induced and that
our results may not be applicable to all memory cells.
The distinctive functions of memory CD4 T cells have been
recognized for many years (41). Here we demonstrate that the
response of memory CD4 T cell to reactivation with soluble
antigen is also markedly distinct from that of naive CD4 T cells.
Whereas activation with soluble antigen alters the survival of
memory CD4 T cells following reactivation, it does not, by itself,
silence these cells. Our studies demonstrate that memory CD4
T cells must be activated at least twice, a first hit to damage the
survival capacity of the cell, and a second hit to cause cell death.
This finding has important implications for treatments for al-
lergy, autoimmunity, and transplantation that aim to remove
pathogenic CD4 T cells via peptide immunotherapy (42). Fur-
thermore, understanding the molecular pathways that have gone
awry in memory CD4 T cells exposed to tolerizing signals has the
potential to highlight pathways to target or remove auto- or
alloreactive T cells. Conversely, it may be possible to manipulate
these pathways to increase the survival of memory CD4 T cells
following infection or vaccination.
Materials and Methods
Animals and Immunizations. Animals were housed and handled either at
National Jewish Health or The University of Glasgow in accordance with local
Animal Care and Use Committee or UK HomeOffice regulations, respectively.
Female C57BL/6 mice (The Jackson Laboratory or Harlan) were first immu-
nized at 6–8 wk of age. To generate memory cells, mice were immunized i.v.
with 10 μg of 3K peptide (FEAQKAKANKAVD) (JPT) and 10 μg of LPS (Sigma).
To induce tolerance, age-matched naive mice and mice that had been
Fig. 6. Memory CD4 T cells reactivated twice with antigen alone do not survive and therefore cannot provide accelerated help for antibody production. B6
mice were immunized with/without 3K peptide and LPS i.v. as indicated with immunizations given 40 d apart. Six days following immunization with 3K-OVA
and alum i.p., the numbers of splenic CD4 T cells that were IAb/3K tetramer+ CD44hi were examined (A) and the levels of anti-OVA IgG in the serum de-
termined (B). In A, each point represents a mouse and the lines show the mean of the group, * indicates groups with means significantly greater than
background, determined by staining naive splenoctyes with IAb/3K tetramer, the mean of which is indicated by the x axis. In B, error bars are SEM. In both, the
data are combined from two experiments with four mice per group and in B, significant differences are indicated by *P < 0.05, **P < 0.01, and ***P < 0.001.
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immunized with 3K peptide and LPS 32–40 d earlier (memory mice) were
injected with 10 μg of 3K peptide i.v. The 3K was conjugated to maleimide-
activated OVA as described by the manufacturer (Pierce). A total of 5 μg of
3K-OVA in 25 μL of PBS was injected into the footpads of restrained mice.
Footpad measurements were taken prior and each day following the in-
jection using a Series 500 Caliper (Mitutoyo). The 3K-OVA peptide/protein
conjugates were tumbled with alum (Alydrogel; Brenntag) for 2 h at room
temperature and each mouse received 1 μg of 3K/OVA with 0.1 mg of alum
intraperitoneally (i.p). BrdU was delivered either as an i.p. injection of 1 mg
in PBS or continuously for 3 d in drinking water at 0.8 mg/mL. The BrdU
drinking water was changed daily and protected from light at all times.
Flow Cytometry. Phycoerythrin-labeled IAb/3K was produced as described
(43). Single-cell suspensions from the spleens of immunized mice were
stained with tetramer at 37 °C for 2 h. Antibodies to surface markers were
added and the cells incubated for an additional 20 min. Tetramer-positive
cells were defined by gating on live CD4 + CD44hi cells that were CD8, B220,
F4/80, MHC class II negative (the dump gate). Antibodies were either from
BD Biosciences, eBioscience, or BioLegend. For analysis of intracellular cas-
pase activation, MHC class II tetramer-stained cells were incubated with
a fluorescent inhibitor of caspase (FLICA) containing a DEVD sequence that
binds to active caspase 3 and 7 as described by the manufacturer (Molecular
Probes, Life Technologies). These cells were then fixed using cytofix/cyto-
perm (BD Biosciences) and stained with anti-Bcl2 (BioLegend). A total of 2–5
million events were collected on a CyAn ADP (Beckman Coulter), and data
analyzed using FlowJo version 9.6 (TreeStar).
ELISA. The 96-well immulon plates were coated with ovalbumin protein at
100 μg/mL in PBS overnight at 4 °C. Following washing, the plates were
blocked with 10% (vol/vol) FCS/PBS before serum samples were added and
titrated down the plate. To determine relative units, we used a positive
control serum sample from B6 mice that contained OVA-specific antibody on
each plate. We also included titrated serum from naive mice to set the level
of background OD. The samples were incubated overnight at 4 °C. Plates
were washed and alkaline phosphatase-conjugated anti-IgG1 (BD Bio-
sciences) detection antibodies were added. Plates were washed again and
p-nitrophenyl phosphate substrate diluted in glycine buffer was added to
each well. Plates were allowed to develop and 405 nm absorbance values
were collected on Elx808 microplate reader.
Statistics. Data are presented as indicated in the figure legends. Statistical
significance was determined using either Student’s two-tailed t test (when
two groups are compared) or ANOVA (when more than two groups are
compared) followed by Bonferroni posttest analysis (for normally distributed
data) or Dunn’s multiple comparison test (for nonparametric data) to de-
termine differences between the groups. All statistical analysis was per-
formed using GraphPad Prism software (version 5).
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